PHILADELPHIA, PA — Latus Bio Inc. (Latus) will showcase its groundbreaking progress in AAV capsid variants—AAV-DB-3 and AAV-Ep+—at the 2025 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting in New Orleans, LA. These innovations mark significant advancements in gene therapy applications, targeting Huntington’s Disease and CLN2 Batten Disease.
“Over the last year, our progress on two preclinical gene therapy programs as well as our novel AAV capsid discovery platform has been remarkable,” said P. Peter Ghoroghchian, MD, PhD, CEO of Latus. “We are excited to share novel findings that have the potential to transform the treatment landscape of patients with genetic diseases.”
Latus will present data on its lead capsid AAV-Ep+, developed for an investigational gene therapy, LTS-101, aimed at addressing CLN2 Batten Disease. Preclinical results demonstrate promising safety, biodistribution, and efficacy at low vector doses in animal models, underscoring its clinical potential. Three poster presentations on LTS-101 will provide insights into its innovative approach, including its intracerebroventricular delivery mechanism.
For Huntington’s Disease, Latus will present findings on its AAV-DB-3 variant, designed to deliver microRNA targeting the genetic mechanism of somatic expansion. Studies highlight AAV-DB-3’s ability to target neural cells effectively and slow disease progression in experimental models. Notably, an oral presentation will explore the variant’s ability to mitigate genetic instability linked to Huntington’s Disease.
Additionally, Latus will offer an invited oral presentation on its capsid discovery platform. The platform focuses on designing AAV capsids with high precision for targeted delivery to specific tissues, enhancing therapeutic outcomes while reducing dose requirements.
These studies underscore Latus’ efforts to develop next-generation gene therapies for severe genetic conditions with unmet medical needs. The company’s pipeline aims to address diseases affecting both the central nervous system, including the cortex and deep brain regions, and peripheral tissues such as the ear, eye, and heart.
Latus’ ASGCT presentations exemplify its mission to transform gene therapy for patients worldwide, creating solutions that move beyond current limitations in the field.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.